Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aratana Theraptcs (PETX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 171,409
  • Shares Outstanding, K 48,974
  • Annual Sales, $ 35,410 K
  • Annual Income, $ -14,720 K
  • 60-Month Beta 1.36
  • Price/Sales 4.88
  • Price/Cash Flow N/A
  • Price/Book 1.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.10
  • Number of Estimates 3
  • High Estimate -0.09
  • Low Estimate -0.11
  • Prior Year -0.19
  • Growth Rate Est. (year over year) +47.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.43 +2.04%
on 04/18/19
4.10 -14.63%
on 03/20/19
-0.31 (-8.14%)
since 03/18/19
3-Month
3.30 +6.06%
on 03/13/19
4.59 -23.75%
on 01/22/19
-0.92 (-20.81%)
since 01/18/19
52-Week
3.30 +6.06%
on 03/13/19
7.16 -51.12%
on 11/08/18
-1.71 (-32.82%)
since 04/18/18

Most Recent Stories

More News
Research Report Identifies Diamondrock Hospitality, Essex Property Trust, Tenet Healthcare, ARMOUR Residential REIT, Mack-Cali Realty, and Aratana Therapeutics with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Diamondrock Hospitality Company...

ARR : 19.76 (-0.25%)
CLI : 22.68 (+1.43%)
ESS : 278.29 (+1.33%)
DRH : 10.78 (+0.47%)
PETX : 3.50 (-0.85%)
THC : 23.41 (+2.00%)
Aratana (PETX) Reports Q4 Loss, Misses Revenue Estimates

Aratana (PETX) delivered earnings and revenue surprises of -63.64% and -24.82%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

PETX : 3.50 (-0.85%)
Aratana: 4Q Earnings Snapshot

LEAWOOD, Kan. (AP) _ Aratana Therapeutics Inc. (PETX) on Tuesday reported a loss of $8.6 million in its fourth quarter.

PETX : 3.50 (-0.85%)
Aratana Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 12, 2019 / Aratana Therapeutics, Inc. (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 12, 2019, 2018 at...

PETX : 3.50 (-0.85%)
Aratana Therapeutics to Participate at Upcoming Investment Conferences

Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, plans on attending the following upcoming...

PETX : 3.50 (-0.85%)
Aratana Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results

Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, will host a live conference call on...

PETX : 3.50 (-0.85%)
Aratana Therapeutics Appoints Rhonda Hellums Chief Financial Officer

Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the appointment of Rhonda...

PETX : 3.50 (-0.85%)
Aratana Therapeutics Sees Hammer Chart Pattern: Time to Buy?

Aratana Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

PETX : 3.50 (-0.85%)
Watch for Aratana Therapeu to Potentially Pullback After Gaining 1.58% Yesterday

Aratana Therapeu (NASDAQ:PETX) traded in a range yesterday that spanned from a low of $4.36 to a high of $4.51. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of...

PETX : 3.50 (-0.85%)
Aratana Therapeutics (PETX) in Focus: Stock Moves 6.8% Higher

Aratana Therapeutics (PETX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

BLCM : 3.06 (-4.67%)
PETX : 3.50 (-0.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade PETX with:

Business Summary

Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative...

See More

Key Turning Points

2nd Resistance Point 3.64
1st Resistance Point 3.57
Last Price 3.50
1st Support Level 3.43
2nd Support Level 3.36

See More

52-Week High 7.16
Fibonacci 61.8% 5.69
Fibonacci 50% 5.23
Fibonacci 38.2% 4.77
Last Price 3.50
52-Week Low 3.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar